Session 1 - Looking Towards The Future: Lessons Learned for Cardio-Oncology from the COVID 19 Pandemic

Dr. Iskra Pusic is Associate Professor in the Division of Oncology, Department of Internal Medicine, at Washington University School of Medicine in St. Louis, MO. Dr. Pusic’s research focuses on long-term complications after allogeneic hematopoietic cell transplantation, particularly Graft-versus-Host Disease (GvHD) and survivorship. Dr. Pusic is a member of the Chronic GvHD Consortium, Clinical Trials Network and Center for International Blood and Marrow Transplant Research - GvHD and Late Effects Working Committees. She was actively involved in the Steering Committee for 2014 and 2021 NIH Chronic GvHD Consensus Development Projects on etiology and prevention of chronic GvHD, and measuring therapeutic response in chronic GvHD trials. She has been a principal investigator on multiple institutional studies and co-investigator on several large multicenter studies focusing on both acute and chronic GvHD. Dr. Pusic was a co-author on a recent Nature publication suggesting that SARS-CoV-2 infection induces a robust antigen-specific, long-lived humoral immune response in humans.

Dr. Joerg Herrmann graduated from Ruhr University medical school in Bochum, Germany and completed his internal medicine residency and cardiovascular diseases and interventional cardiology fellowship at the Mayo Clinic in Rochester, MN. Thereafter, he joined the division of cardiovascular diseases at the Mayo Clinic Rochester. He is a Professor of Medicine at the Mayo Clinic College of Medicine and currently serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He has published over 100 articles in peer-reviewed journals and has received NIH grant funding. He also serves as the associated editor of Trends in Cardiovascular Medicine and Practice Update.

Lawrence N. Shulman, MD, MACP, FASCO, is professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania, deputy director for Clinical Services at the Abramson Cancer Center. In this capacity, he helps to lead the Cancer Quality program and strategic development of Cancer Services across the University of Pennsylvania Health System. He is the immediate past-chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. He is the director of the Center for Global Cancer Medicine at the Abramson Cancer Center, University of Pennsylvania. He serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor’s Advisory Council for Rwanda’s University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership. He is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017. He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Dr Scherrer-Crosbie is the Director of the Echocardiography Laboratory and a Professor of Medicine at the Hospital of the University of Pennsylvania in Philadelphia, PA, USA. She has a longstanding interest in the interactions of cancer, chemotherapy and heart failure. Throughout her research career, she has also successfully developed a number of novel techniques in the field of echocardiography. She has published over 145 papers and has been continuously funded by the American Heart Association, the American Society of Echocardiography and the NIH. She is involved in the ACC, AHA, APS and ASE, having chaired the cardiovascular sessions at Experimental Biology 2016-2019 and the American Society of Echocardiography 2019 Scientific Sessions. Over the last several years, she has been the PI of 2 multicenter prospective studies, one investigating the value of echocardiographic and blood biomarkers in the prediction of cardiotoxicity in women treated with anthracyclines and trastuzumab, and one investigating the role of statins in the prevention of cardiotoxicity.